FEMSelect

FEMSelect is an Israeli-based startup with a focus on health care. The company has developed EnPlace™, a minimally invasive and meshless system specifically designed for suturing ligaments of the pelvic floor to address the challenges of Pelvic Organ Prolapse (POP) procedures. This innovative approach is aimed at providing a simpler and less invasive alternative to the current standard of care dissection approach.

One of the critical issues that FEMSelect aims to address is the prevalent and bothersome medical condition of Pelvic Organ Prolapse (POP), which affects a significant percentage of women globally. The current standard of care, which often involves hysterectomy or complicated mesh surgery, has been associated with various complications, leading to a substantial unmet need for a simple and safe pelvic floor repair system.

The global market for POP devices is estimated at $10 billion and is growing due to the aging population, presenting a significant opportunity for FEMSelect's EnPlace™ system. The approach stands out with its FDA clearance and CE Marking, offering a minimally invasive surgical solution that is simpler and devoid of deep dissection and mesh. The technology has been protected by global and US patents, and has undergone successful testing in the US, Germany, and Israel, paving the way for commercial availability in the US and Israel.

The company's recent $547.50K Convertible Note investment at 20 May 2024 from Robin Hood Ventures reflects a notable endorsement of FEMSelect's potential to provide an impactful and much-needed solution in the field of women's health.